Compounds > olmesartan medoxomil
Page last updated: 2024-09-03

olmesartan medoxomil and Cardiomyopathies

olmesartan medoxomil has been researched along with Cardiomyopathies in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kasal, DA; Mandarim-de-Lacerda, CA; Neves, MF; Oigman, W1
Hasegawa, K; Kishimoto, C; Kita, T; Nimata, M; Okabe, TA; Shioji, K; Yuan, Z1
Higaki, J; Matsumoto, K; Moriguchi, A; Morishita, R; Nakagami, H; Nakamura, T; Ogihara, T; Sakonjo, H; Taniyama, Y1

Other Studies

3 other study(ies) available for olmesartan medoxomil and Cardiomyopathies

ArticleYear
Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor.
    Histology and histopathology, 2008, Volume: 23, Issue:10

    Topics: Allopurinol; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Enzyme Inhibitors; Hypertension; Imidazoles; Male; Myocardium; NG-Nitroarginine Methyl Ester; Olmesartan Medoxomil; Rats; Rats, Wistar; Tetrazoles; Time Factors; Uric Acid; Ventricular Remodeling; Xanthine Oxidase

2008
Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 289, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoimmune Diseases; Blood Pressure; Body Weight; Cardiomyopathies; Disease Models, Animal; Heart Failure; Heart Rate; Imidazoles; Interleukin-1; Lymphocytes; Myocarditis; Myocardium; Myosins; Olmesartan Medoxomil; Organ Size; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Tetrazoles

2005
Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters.
    Circulation, 2000, Jul-11, Volume: 102, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cells, Cultured; Collagen; Cricetinae; Extracellular Matrix; Fibroblasts; Fibrosis; Hepatocyte Growth Factor; Humans; Imidazoles; In Vitro Techniques; Male; Matrix Metalloproteinase 1; Muscle Fibers, Skeletal; Myocardium; Olmesartan Medoxomil; Rats; Tetrazoles; Thiazepines; Ventricular Remodeling

2000